Name: Azetukalner (XEN1101) in Focal onset seizures: Effects of Azetukalner on other drugs
Published: 2026-09-21T21:41:53-04:00

Product information and disease description Product description Product information Drug/Drug, drug/disease interactions

Effects of Azetukalner on other drugs

3 evidence topics · 2 sources

In vitro cytochrome P450 inhibition and induction

“At in vitro concentrations of 3 μmol/L, which are much higher than those anticipated to be clinically efficacious, azetukalner did not cause direct inhibition of CYP1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A4, nor did it cause time-dependent inhibition” (opens the source at this quote in a new tab)
“Likewise, no clinically meaningful induction of the pregnane X nuclear receptor (PXR), which is associated with CYP3A4 expression levels, was observed at azetukalner concentrations of 0.1–1 μmol/L” (opens the source at this quote in a new tab)

Low potential for drug interactions in clinical use

“A mechanism of action that differs from that of currently marketed ASMs and a low potential for drug–drug interactions make azetukalner a good candidate for adjunctive therapy in focal-seizure patients receiving any type of concomitant medication. Additional advantages include the feasibility of once daily dosing without titration.” (opens the source at this quote in a new tab)

No dose adjustment of concomitant antiseizure medications

“Azetukalner has the potential to deliver much needed innovation to treat people living with focal seizures, with strong efficacy, a differentiated mechanism of action that may enable rational polytherapy, once-daily dosing with no dose adjustments for other antiseizure medications, and a consistent and generally well-tolerated safety profile” (opens the source at this quote in a new tab)

Effect on hormonal contraceptives

No evidence found.